EBS:NYE-Emergent Biosolutions Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 6.99

Change

+0.09 (+1.30)%

Market Cap

N/A

Volume

0.88M

Analyst Target

USD 112.29
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-19 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
ZTS Zoetis Inc

-3.24 (-1.65%)

USD 83.17B
HLN Haleon plc

-0.09 (-0.85%)

USD 47.33B
TAK Takeda Pharmaceutical Co Ltd A..

+0.11 (+0.74%)

USD 46.60B
RDY Dr. Reddy’s Laboratories Ltd..

-0.44 (-0.56%)

USD 13.37B
CTLT Catalent Inc

-0.21 (-0.35%)

USD 10.83B
ELAN Elanco Animal Health

+0.42 (+2.87%)

USD 7.15B
BHC Bausch Health Companies Inc

+0.16 (+2.00%)

USD 3.00B
AMRX Amneal Pharmaceuticals, Inc. C..

+0.10 (+1.15%)

USD 2.73B
CPHI China Pharma Holdings Inc

-0.01 (-2.70%)

USD 3.94M
YCBD cbdMD Inc

-0.01 (-2.24%)

USD 1.92M

ETFs Containing EBS

EBNK:CA Evolve European Banks Enh.. 5.01 % 0.00 %

+0.20 (+1.05%)

CAD 3.36M
EMUM:SW iShares MSCI EMU Mid Cap .. 1.86 % 0.00 %

N/A

USD 0.13B
LGGE:XETRA L&G Quality Equity Divide.. 1.38 % 0.00 %

+0.13 (+1.05%)

USD 0.03B
LDEU:LSE L&G Quality Equity Divide.. 1.37 % 0.00 %

+0.11 (+1.05%)

USD 0.04B
LDEG:LSE L&G Quality Equity Divide.. 1.30 % 0.00 %

+7.40 (+1.05%)

N/A
PRFZ Invesco FTSE RAFI US 1500.. 0.28 % 0.39 %

+0.83 (+1.05%)

USD 2.45B
IS3H:F iShares IV Public Limited.. 0.00 % 0.00 %

+0.69 (+1.05%)

N/A
EL43:XETRA Deka MSCI Europe MC UCITS.. 0.00 % 0.00 %

+0.18 (+1.05%)

USD 0.02B
IS3H:XETRA iShares MSCI EMU Mid Cap .. 0.00 % 0.00 %

+0.76 (+1.05%)

USD 0.13B
IVES Amplify ETF Trust 0.00 % 0.00 %

+1.24 (+1.05%)

USD 0.02B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 191.25% 100% F 100% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 191.25% 100% F 100% F
Trailing 12 Months  
Capital Gain 103.20% 93% A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 103.20% 93% A 98% N/A
Trailing 5 Years  
Capital Gain -86.31% 21% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -86.31% 21% F 3% F
Average Annual (5 Year Horizon)  
Capital Gain -34.50% 6% D- 1% F
Dividend Return -34.50% 6% D- 1% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 55.71% 31% F 15% F
Risk Adjusted Return -61.93% 13% F 4% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector